Next-generation Cellular Therapies, T cell Engagers, and Combinations- Hybrid

The 2026 Spring Scientific program will feature in-depth explorations and discussions of recent scientific breakthroughs, cutting-edge technologies, and the newest clinical studies that address the development and advancement of novel immuno-oncology agents and how these agents can be combined with other therapies to overcome tumor evasion of immunity.